Abstract |
Indacaterol is a novel once-daily long-acting β2-agonist (LABA) for the treatment of chronic obstructive pulmonary disease ( COPD) that is currently completing Phase II and Phase III trials. It represents the first of a group of drugs now referred to as the 'ultra-LABAs'. It has recently gained approval in Europe, and is pending regulatory review in the USA. Indacaterol produces a rapid and sustained bronchodilation that lasts for at least 24 h in patients with COPD. To date, 1-year studies with indacaterol indicate that it can be taken once daily with good overall safety and tolerability profiles. The therapeutic potential for indacaterol is supported by data on patient-reported outcomes with an improvement in symptoms such as dyspnea, exercise capacity and quality of life, and a reduction in exacerbations. It is likely that indacaterol could be used in conjunction with other agents such as inhaled corticosteroids and anticholinergics for the treatment of COPD as a single once-daily combination treatment.
|
Authors | Christopher K M Hui, Kian F Chung |
Journal | Expert review of respiratory medicine
(Expert Rev Respir Med)
Vol. 5
Issue 1
Pg. 9-16
(Feb 2011)
ISSN: 1747-6356 [Electronic] England |
PMID | 21348581
(Publication Type: Journal Article)
|
Chemical References |
- Adrenal Cortex Hormones
- Adrenergic beta-Agonists
- Cholinergic Antagonists
- Indans
- Quinolones
- indacaterol
|
Topics |
- Adrenal Cortex Hormones
(therapeutic use)
- Adrenergic beta-Agonists
(adverse effects, pharmacokinetics, therapeutic use)
- Cholinergic Antagonists
(therapeutic use)
- Drug Therapy, Combination
- Drug-Related Side Effects and Adverse Reactions
- Humans
- Indans
(adverse effects, pharmacokinetics, therapeutic use)
- Pulmonary Disease, Chronic Obstructive
(drug therapy, physiopathology)
- Quinolones
(adverse effects, pharmacokinetics, therapeutic use)
- Treatment Outcome
|